• Ulrich Schwabe
  • Thomas Rabe


Die wichtigsten Gruppen der Sexualhormone sind Östrogenpräparate und die Kontrazeptiva.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Castelo-Branco C., Vicente J.J., Figueras F,. Sanjuan A., Martinez de Osaba M.J., Casals E. et al. (2000): Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34: 161–168.PubMedCrossRefGoogle Scholar
  2. Cauley J.A., Black D.M., Barrett-Connor E., Harris F., Shields K., Applegate W., Cummings S.R. (2001): Effects of hormone replacement therapy on clinical fractures and height loss: the heart and estrogen/Progestin replacement study (HERS). Am. J. Med. 110: 442–450.PubMedCrossRefGoogle Scholar
  3. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., Cummings S.R. (1995): Estrogen replacement therapy and fractures in older women. Ann. Intern. Med. 122: 9–16.PubMedCrossRefGoogle Scholar
  4. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E. et al. (1995): The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332: 1589–1593.PubMedCrossRefGoogle Scholar
  5. Collaborative Group on Hormonal Factors in Breast Cancer (1997): Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350: 1047–1059.CrossRefGoogle Scholar
  6. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K. et al. for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999): Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282: 637–645.PubMedCrossRefGoogle Scholar
  7. Farish E., Barnes J.F., Fletcher C.D., Ekevall K., Calder A., Hart D.M. (1999): Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progesteron regimen. Menopause 6: 98–104.PubMedCrossRefGoogle Scholar
  8. Fisher B., Constantino J.P., Wickerham L.D., Redmond C.K. et al. (1998): Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer I. 90: 1371–1388.CrossRefGoogle Scholar
  9. Grady D. (2002): A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA 287: 2130–2137.PubMedCrossRefGoogle Scholar
  10. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. (2000): A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133: 933–1001.PubMedCrossRefGoogle Scholar
  11. Herrington D.M., Reboussin D.M., Brosnihan K. B., Sharp P.C., Shumaker S.A., Snyder T.E. et al. (2000): Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N. Engl. J. Med. 343: 522–529.PubMedCrossRefGoogle Scholar
  12. Hully S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. (1998): Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605–613.CrossRefGoogle Scholar
  13. Jick H., lick S.S., Gurewich V., Myers M.W., Vasilakis C. (1995): Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 1589–1593.PubMedCrossRefGoogle Scholar
  14. Katz S., Morales A.J. (1998): Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DS) as therapeutic options in menopause. Semin. Reprod. Endocrinol. 16: 161–170.PubMedCrossRefGoogle Scholar
  15. Keating N.L., Cleary P.D., Rossi A.S., Zaslaysky A.M.,Ayanian J.Z. (1999): Use of hormone replacement therapy by postmenopausal women in the United States. Ann. Intern. Med. 130: 545–553.PubMedCrossRefGoogle Scholar
  16. Kemmeren J.M., Algra A., Grobbee D.E. (2001): Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit. Med. J. 323: 1–9.CrossRefGoogle Scholar
  17. König H.J. (1991): Hirnkreislaufstörungen unter Einnahme gestodenhaltiger hormonaler oraler Kontrazeptiva - Kausalität oder Koinzidenz? Dtsch. Ärztebl. 91: C-1745–1748.Google Scholar
  18. Lamberts S.W., van den Beld A.W., van der Lely A.J. (1997): The endocrinology of aging. Science 278: 419–424.PubMedCrossRefGoogle Scholar
  19. Manson J.E., Martin K.A. (2001): Postmenopausal hormone-replacement therapy. N. Engl. J. Med. 345: 34–40.PubMedCrossRefGoogle Scholar
  20. Mosca L., Collins P., Herrington D.M., Mendelsohn M.E., Pasternak R.C., Robertson R.M. et al. (2001): Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 104: 499–503.PubMedCrossRefGoogle Scholar
  21. Mulnard R.A., Cotman C.W., Kawas C., van Dyck C.H., Sano M., Doody R. et al. (2000): Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA 283: 1007–1015.PubMedCrossRefGoogle Scholar
  22. Oelkers W., Helmerhorst F.M., Wuttke W., Heithecker R. (2000): Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol. Endocrinol. 14: 204–213.PubMedCrossRefGoogle Scholar
  23. Powles T., Eeles R., Ashley S., Easton D., Chang J. et al. (1998): Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen randomised Chemoprevention Trial. Lancet 352: 98–101.PubMedGoogle Scholar
  24. Royal College of General Practitioners Oral Contraception Study (1981): Further analysis of mortality in oral contraceptive users. Lancet I: 541–546.Google Scholar
  25. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. (2000): Menopausal estrogen and estsrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485–491.PubMedCrossRefGoogle Scholar
  26. Spitzer W.O., Lewis M.A., Heinemann L.A.J., Thorogood M., MacRae K.D. (1996): Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit. Med. J. 312: 83–88.PubMedCrossRefGoogle Scholar
  27. Tang M.-X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H. (1996): Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 348: 429–432.PubMedCrossRefGoogle Scholar
  28. Thiel C., Heinemann L.A. for the German Cohort Study on Women’s Health (2001): Reasons for the change in HRT therapy from the perspective of women. Results of the German Cohort Study on Women’s Health. Zentralbl. Gynäkol. 123: 390–398.PubMedCrossRefGoogle Scholar
  29. Veronesi U., Maisonneuve P., Costa A., Saccini V. Maltoni C. et al. on behalf of the Italian Tamoxifen Prevention Study (1998): Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial amoung hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352: 93–97.PubMedGoogle Scholar
  30. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995): Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582–1588.Google Scholar
  31. Writing Group for the Women’s Health Initiative (2002): Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Ulrich Schwabe
  • Thomas Rabe

There are no affiliations available

Personalised recommendations